Loading company…
Perseus Proteomics develops antibody-based therapeutics and research reagents.
Perseus Proteomics uses antibody technologies to develop therapeutics, including antibodies conjugated with radioisotopes or toxins to target cancer cells. Its work includes clinical trials of PPMX-T003 and PPMX-T002 in Japan. Based in Tokyo, Japan, the company was founded in 2001.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in